IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 97 filers reported holding IMMUNOVANT INC in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,985,951 | +527.5% | 807,136 | +210.1% | 0.01% | +500.0% |
| Q2 2023 | $4,938,176 | +7.7% | 260,315 | -12.0% | 0.00% | – |
| Q1 2023 | $4,586,757 | +104.4% | 295,729 | +133.9% | 0.00% | – |
| Q4 2022 | $2,244,470 | +272.2% | 126,449 | +17.1% | 0.00% | – |
| Q3 2022 | $603,000 | -6.1% | 107,964 | -34.4% | 0.00% | – |
| Q2 2022 | $642,000 | -54.9% | 164,518 | -36.3% | 0.00% | – |
| Q1 2022 | $1,422,000 | -79.3% | 258,231 | -68.0% | 0.00% | – |
| Q4 2021 | $6,870,000 | +9.2% | 806,222 | +11.3% | 0.00% | -100.0% |
| Q3 2021 | $6,294,000 | -3.7% | 724,283 | +17.2% | 0.00% | – |
| Q2 2021 | $6,534,000 | +384.4% | 618,171 | +635.1% | 0.00% | – |
| Q1 2021 | $1,349,000 | -15.9% | 84,098 | +142.3% | 0.00% | – |
| Q4 2020 | $1,604,000 | +159.1% | 34,710 | +97.2% | 0.00% | – |
| Q3 2020 | $619,000 | – | 17,602 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |